Literature DB >> 11437599

Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells.

N S Seo1, J R Hollister, D L Jarvis.   

Abstract

The baculovirus-insect cell expression system is widely used to produce recombinant mammalian glycoproteins, but the glycosylated end products are rarely authentic. This is because insect cells are typically unable to produce glycoprotein glycans containing terminal sialic acid residues. In this study, we examined the influence of two mammalian glycosyltransferases on N-glycoprotein sialylation by the baculovirus-insect cell system. This was accomplished by using a novel baculovirus vector designed to express a mammalian alpha2,6-sialyltransferase early in infection and a new insect cell line stably transformed to constitutively express a mammalian beta1,4-galactosyltransferase. Various biochemical assays showed that a foreign glycoprotein was sialylated by this virus-host combination, but not by a control virus-host combination, which lacked the mammalian glycosyltransferase genes. Thus, this study demonstrates that the baculovirus-insect cell expression system can be metabolically engineered for N-glycoprotein sialylation by the addition of two mammalian glycosyltransferase genes. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437599     DOI: 10.1006/prep.2001.1432

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  18 in total

1.  Novel baculovirus expression vectors that provide sialylation of recombinant glycoproteins in lepidopteran insect cells.

Authors:  D L Jarvis; D Howe; J J Aumiller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins.

Authors:  Jared J Aumiller; Jason R Hollister; Donald L Jarvis
Journal:  Glycobiology       Date:  2003-02-20       Impact factor: 4.313

Review 3.  Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production.

Authors:  Donald L Jarvis
Journal:  Virology       Date:  2003-05-25       Impact factor: 3.616

Review 4.  Protein N-glycosylation in the baculovirus-insect cell system.

Authors:  Xianzong Shi; Donald L Jarvis
Journal:  Curr Drug Targets       Date:  2007-10       Impact factor: 3.465

5.  A new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency.

Authors:  Ann M Toth; Chu-Wei Kuo; Kay-Hooi Khoo; Donald L Jarvis
Journal:  J Biotechnol       Date:  2014-04-24       Impact factor: 3.307

6.  Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans.

Authors:  Jason Hollister; Eckart Grabenhorst; Manfred Nimtz; Harald Conradt; Donald L Jarvis
Journal:  Biochemistry       Date:  2002-12-17       Impact factor: 3.162

7.  Expression and Characterization of Human β-1, 4-Galactosyltransferase 1 (β4GalT1) Using Silkworm-Baculovirus Expression System.

Authors:  Daisuke Morokuma; Jian Xu; Masato Hino; Hiroaki Mon; Jasmeen S Merzaban; Masateru Takahashi; Takahiro Kusakabe; Jae Man Lee
Journal:  Mol Biotechnol       Date:  2017-05       Impact factor: 2.695

8.  Evidence for a sialic acid salvaging pathway in lepidopteran insect cells.

Authors:  Jason Hollister; Harald Conradt; Donald L Jarvis
Journal:  Glycobiology       Date:  2003-02-20       Impact factor: 4.313

9.  Innovative use of a bacterial enzyme involved in sialic acid degradation to initiate sialic acid biosynthesis in glycoengineered insect cells.

Authors:  Christoph Geisler; Donald L Jarvis
Journal:  Metab Eng       Date:  2012-09-27       Impact factor: 9.783

10.  A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells.

Authors:  Hideaki Mabashi-Asazuma; Chu-Wei Kuo; Kay-Hooi Khoo; Donald L Jarvis
Journal:  Glycobiology       Date:  2013-12-20       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.